NYSE:NVRO - Nevro Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $40.63 +1.93 (+4.99 %) (As of 01/15/2019 04:00 PM ET)Previous Close$38.70Today's Range$38.64 - $41.4752-Week Range$34.75 - $94.34Volume596,111 shsAverage Volume882,210 shsMarket Capitalization$1.19 billionP/E Ratio-32.50Dividend YieldN/ABeta-0.12 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. Its solution for chronic pain also includes HF10 Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. The company sells its products through its direct sales force, and a network of sales agents and independent distributors. Nevro Corp. was founded in 2006 and is headquartered in Redwood City, California. Receive NVRO News and Ratings via Email Sign-up to receive the latest news and ratings for NVRO and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNYSE:NVRO Previous Symbol CUSIPN/A Webwww.nevro.com Phone650-251-0005Debt Debt-to-Equity Ratio0.62 Current Ratio8.05 Quick Ratio6.31Price-To-Earnings Trailing P/E Ratio-32.50 Forward P/E Ratio-27.27 P/E GrowthN/A Sales & Book Value Annual Sales$326.67 million Price / Sales3.75 Cash FlowN/A Price / Cash FlowN/A Book Value$8.41 per share Price / Book4.83Profitability EPS (Most Recent Fiscal Year)($1.25) Net Income$-36,650,000.00 Net Margins-11.64% Return on Equity-17.89% Return on Assets-9.76%Miscellaneous Employees676 Outstanding Shares30,160,000Market Cap$1.19 billion OptionableOptionable Nevro (NYSE:NVRO) Frequently Asked Questions What is Nevro's stock symbol? Nevro trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVRO." How were Nevro's earnings last quarter? Nevro Corp (NYSE:NVRO) released its quarterly earnings results on Monday, November, 5th. The medical equipment provider reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.30) by $0.07. The medical equipment provider had revenue of $95.60 million for the quarter, compared to analysts' expectations of $94.29 million. Nevro had a negative return on equity of 17.89% and a negative net margin of 11.64%. The firm's revenue for the quarter was up 16.2% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.21) earnings per share. View Nevro's Earnings History. When is Nevro's next earnings date? Nevro is scheduled to release their next quarterly earnings announcement on Thursday, February 28th 2019. View Earnings Estimates for Nevro. What guidance has Nevro issued on next quarter's earnings? Nevro updated its FY 2018 earnings guidance on Monday, January, 7th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $386.9-387.4 million, compared to the consensus revenue estimate of $385.46 million.Nevro also updated its Q4 2018 guidance to EPS. What price target have analysts set for NVRO? 11 equities research analysts have issued 1-year target prices for Nevro's stock. Their forecasts range from $35.00 to $105.00. On average, they expect Nevro's stock price to reach $59.5455 in the next year. This suggests a possible upside of 46.6% from the stock's current price. View Analyst Price Targets for Nevro. What is the consensus analysts' recommendation for Nevro? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last year. There are currently 3 sell ratings, 5 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Nevro. What are Wall Street analysts saying about Nevro stock? Here are some recent quotes from research analysts about Nevro stock: 1. Northland Securities analysts commented, "We are introducing our FY20 numbers, and our rating / PT remains the same." (1/11/2019) 2. According to Zacks Investment Research, "Nevro Corp. is a medical device company. It engages in developing and commercializing a neuromodulation platform for the treatment of chronic pain. The Company provides pain relief to the customers suffering from low back pain and types of chronic pains. Nevro has developed and commercialized the Senza (R) spinal cord stimulation (SCS) system for the treatment of chronic pain. Senza, HF10, Nevro and the Nevro logo are trademarks of the company. Nevro Corp. is headquartered in Menlo Park, California. " (1/10/2019) Has Nevro been receiving favorable news coverage? News headlines about NVRO stock have been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Nevro earned a media sentiment score of 1.9 on InfoTrie's scale. They also assigned press coverage about the medical equipment provider a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the near term. Who are some of Nevro's key competitors? Some companies that are related to Nevro include ICU Medical (ICUI), Penumbra (PEN), Insulet (PODD), Globus Medical (GMED), Novocure (NVCR), Integra Lifesciences (IART), Cantel Medical (CMD), Merit Medical Systems (MMSI), Tandem Diabetes Care (TNDM), NuVasive (NUVA), Glaukos (GKOS), Irhythm Technologies (IRTC), Mazor Robotics (MZOR), Atrion (ATRI) and K2M Group (KTWO). Who are Nevro's key executives? Nevro's management team includes the folowing people: Mr. Rami Elghandour, Pres, CEO & Director (Age 40)Mr. Andrew H. Galligan, Chief Financial Officer (Age 63)Mr. Patrick Schmitz, VP of Operations (Age 59)Mr. Doug Alleavitch, VP of Quality (Age 58)Mr. Kashif Rashid, Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 45) Who are Nevro's major shareholders? Nevro's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Cerebellum GP LLC (0.02%). Company insiders that own Nevro stock include Andrew H Galligan, Michael Enxing, Michael F Demane, Rami Elghandour and Wilfred E Jaeger. View Institutional Ownership Trends for Nevro. Which major investors are buying Nevro stock? NVRO stock was purchased by a variety of institutional investors in the last quarter, including Cerebellum GP LLC. View Insider Buying and Selling for Nevro. How do I buy shares of Nevro? Shares of NVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Nevro's stock price today? One share of NVRO stock can currently be purchased for approximately $40.63. How big of a company is Nevro? Nevro has a market capitalization of $1.19 billion and generates $326.67 million in revenue each year. The medical equipment provider earns $-36,650,000.00 in net income (profit) each year or ($1.25) on an earnings per share basis. Nevro employs 676 workers across the globe. What is Nevro's official website? The official website for Nevro is http://www.nevro.com. How can I contact Nevro? Nevro's mailing address is 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065. The medical equipment provider can be reached via phone at 650-251-0005 or via email at [email protected] MarketBeat Community Rating for Nevro (NYSE NVRO)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 342 (Vote Outperform)Underperform Votes: 221 (Vote Underperform)Total Votes: 563MarketBeat's community ratings are surveys of what our community members think about Nevro and other stocks. Vote "Outperform" if you believe NVRO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVRO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/15/2019 by MarketBeat.com StaffFeatured Article: What are the benefits of a balanced fund?